Literature DB >> 33496855

Lack of awareness of liver organ damage in patients with type 2 diabetes.

Stefano Ciardullo1,2, Tommaso Monti3, Gianluca Perseghin4,5.   

Abstract

AIMS: Liver steatosis, a typical finding in patients with type 2 diabetes (T2D), can lead to cirrhosis and hepatocellular carcinoma. The aim of the present study is to estimate the awareness of liver disease among patients with T2D and whether it differs according to the degree of liver fibrosis estimated by transient elastography (TE).
METHODS: This is a population-based cross-sectional study. We included all patients with T2D that participated in the 2017-2018 cycle of the National Health and Nutrition Examination Survey and underwent a TE examination. Presence of liver steatosis and fibrosis was assessed by the median values of controlled attenuation parameter and liver stiffness measurement, respectively.
RESULTS: Among the 825 patients included in the analysis, 8.1% (95% CI 5.1%-12.7%) of patients with steatosis were aware of having a liver condition. Even if awareness increased proportionally with increasing severity of organ damage, it remained limited even among patients with advanced fibrosis (17.9%, 95% CI 8.8%-33.3%).
CONCLUSIONS: Despite increasing evidence of a frequent hepatic involvement associated with poor prognosis, awareness of suffering of advanced liver disease in patients with T2D is remarkably low, likely reflecting little recognition also among the team of health care professionals.

Entities:  

Keywords:  Awareness; Cirrhosis; Diabetes; Fibroscan; MAFLD; NAFLD; Screening

Year:  2021        PMID: 33496855     DOI: 10.1007/s00592-021-01677-y

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  7 in total

1.  Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.

Authors:  Preya J Patel; Xuan Banh; Leigh U Horsfall; Kelly L Hayward; Fabrina Hossain; Tracey Johnson; Katherine A Stuart; Nigel N Brown; Nivene Saad; Andrew Clouston; Katharine M Irvine; Anthony W Russell; Patricia C Valery; Suzanne Williams; Elizabeth E Powell
Journal:  Intern Med J       Date:  2018-02       Impact factor: 2.048

2.  Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk.

Authors:  Amanda C Wieland; Pamela Mettler; Michael T McDermott; Lori A Crane; Lisa C Cicutto; Kiran M Bambha
Journal:  J Clin Gastroenterol       Date:  2015-01       Impact factor: 3.062

3.  Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort.

Authors:  Amandeep Singh; Amaninder S Dhaliwal; Shailainder Singh; Atul Kumar; Rocio Lopez; Mohit Gupta; Mazen Noureddin; William Carey; Arthur McCullough; Naim Alkhouri
Journal:  Dig Dis Sci       Date:  2019-06-11       Impact factor: 3.199

Review 4.  Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.

Authors:  Fernando Bril; Kenneth Cusi
Journal:  Diabetes Care       Date:  2017-03       Impact factor: 19.112

5.  Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes.

Authors:  Karl Björkström; Stefan Franzén; Björn Eliasson; Mervete Miftaraj; Soffia Gudbjörnsdottir; Ylva Trolle-Lagerros; Ann-Marie Svensson; Hannes Hagström
Journal:  Clin Gastroenterol Hepatol       Date:  2019-04-19       Impact factor: 11.382

6.  Mortality from chronic liver diseases in diabetes.

Authors:  Giacomo Zoppini; Ugo Fedeli; Nicola Gennaro; Mario Saugo; Giovanni Targher; Enzo Bonora
Journal:  Am J Gastroenterol       Date:  2014-06-03       Impact factor: 10.864

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.